Third Rock, GV back Broad spin­out Cel­sius in bid to de­vel­op pre­ci­sion meds for au­toim­mune dis­ease

Third Rock is team­ing up with Google’s ven­ture arm to back a gene ther­a­py start­up step­ping out to­day with $65 mil­lion in new mon­ey. As you might ex­pect with GV’s in­volve­ment, the new ven­ture has a tech­nol­o­gy twist, and it might have its hands on some­thing big for the au­toim­mune world.

Are you ready for a game of buzz­word bin­go? The start­up, called Cel­sius Ther­a­peu­tics, is us­ing new tech in ge­net­ic se­quenc­ing (check) — and a pro­pri­etary ma­chine learn­ing (check) al­go­rithm (check) — to tack­le pre­ci­sion meds (check) for can­cer (check) and au­toim­mune dis­ease. I’ll break that down for you lat­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.